Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.62 |
| ▸ | DRD2 | P14416 | 6/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.62 |
| ▸ | DRD3 | P35462 | 6/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.62 |
| ▸ | HRH1 | P35367 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.62 |
| ▸ | DRD4 | P21917 | 4/20 | 0.62 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.62 |
| ▸ | HTR2C | P28335 | 3/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8831796 | 0.94 | HTR2A (0.66) | HTR2ASLC6A4CHRM2CHRM1DRD2 | |
| SCHEMBL7981739 | 0.88 | HTR2A (0.61) | HTR2ASLC6A4CHRM2CHRM1DRD2 | |
| SCHEMBL5389753 | 0.88 | DRD2 (0.62) | HTR2ACHRM2CHRM1DRD2CHRM3 | |
| SCHEMBL13051501 | 0.88 | HTR2A (0.78) | HTR2ASLC6A4CHRM2CHRM1DRD2 | |
| SCHEMBL17298325 | 0.83 | HTR2A (0.44) | HTR2ASLC6A4CHRM2CHRM1DRD2 | |
| SCHEMBL1764224 | 0.83 | DRD2 (0.60) | CHRM2CHRM1DRD2CHRM3DRD3 | |
| SCHEMBL5384961 | 0.82 | DRD2 (0.59) | CHRM2CHRM1DRD2CHRM3DRD3 | |
| SCHEMBL285431 | 0.81 | HTR2A (0.50) | HTR2ASLC6A4CHRM2CHRM1DRD2 | |
| SCHEMBL17298327 | 0.81 | PIM1 (0.46) | HTR2ASLC6A4CHRM2CHRM1DRD2 | |
| SCHEMBL6961973 | 0.81 | HTR2A (0.68) | HTR2ASLC6A4CHRM2CHRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725431-B2 | Oligomer-tricyclic conjugates | NEKTAR THERAPEUTICS (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725431-B2 | Oligomer-tricyclic conjugates | NEKTAR THERAPEUTICS (US) | 2017-08-08 | — | — | US | disclosed |
| EP-2222342-B1 | OLIGOMER-TRICYCLIC CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8569380-B2 | Oligomer-tricyclic conjugates | NEKTAR THERAPEUTICS (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569380-B2 | Oligomer-tricyclic conjugates | NEKTAR THERAPEUTICS (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100298296-A1 | Oligomer-Tricyclic Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298296-A1 | Oligomer-Tricyclic Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009073154-A1 | OLIGOMER-TRICYCLIC CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| US-6235730-B1 | ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT | JAPAN TOBACCO, INC. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0970954-A1 | 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME | JAPAN TOBACCO INC. (JP) | 2000-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298296-A1 | Oligomer-Tricyclic Conjugates | ABCG2, SLCO1B3, SLC43A1 | HTR2A 1525/4885SLC6A4 297/4885CHRM2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.